|
Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM). |
|
|
Honoraria - Bayer; Boehringer Ingelheim; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD; Novartis; Pfizer; Roche; Takeda |
|
|
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pharmamar |
|
|
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer |
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD Oncology; Pfizer |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Epizyme; Merck Sharp & Dohme; Roche; Sellas Life Sciences; Trizell |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim |
|
|
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Guardant Health; Lilly; Novartis; Pfizer; Roche; Takeda |
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Novartis; Pfizer; Roche |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Epizyme (Inst); Lilly (Inst); Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Ignyta; MSD Oncology; Novartis; Pfizer; Pfizer; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Ignyta; MSD Oncology; Novartis; Pfizer; Roche/Genentech |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer |
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD; Novartis; Pfizer; Roche |
|
Brett Gordon Maxwell Hughes |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Novartis; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech |
Consulting or Advisory Role - Genentech |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech |
Research Funding - Genentech; Pfizer (Inst) |
|
|
Employment - Boehringer Ingelheim |
|
|
Employment - Boehringer Ingelheim |
|
|
Honoraria - AstraZeneca; Lilly; MSD; Pfizer; Roche |
Consulting or Advisory Role - Lilly |
Speakers' Bureau - Lilly; MSD |
Travel, Accommodations, Expenses - Bayer |